ATI Pharmacology Proctored Assessment | 2026
Verified Solutions
1. A patient receiving IV heparin develops a rapid drop in platelet count from 200,000 to
50,000/mm³ after 5 days of therapy. Which antibody is most likely responsible for this
complication?
A. IgA against heparin-platelet factor 4 complex
B. IgG against heparin-platelet factor 4 complex
C. IgM against heparin-antithrombin III complex
D. IgE against heparin-thrombomodulin complex
Answer: B
Rationale: Heparin-induced thrombocytopenia (HIT) is caused by IgG antibodies that bind to
heparin-platelet factor 4 complexes, activating platelets and leading to thrombocytopenia. IgA
and IgM are not the primary immunoglobulins involved. IgE is associated with allergic
reactions, not HIT.
2. A patient with type 2 diabetes mellitus and chronic kidney disease (eGFR 25 mL/min) is
being prescribed a new antihyperglycemic agent. Which of the following would be
contraindicated due to increased risk of lactic acidosis?
A. Liraglutide
B. Metformin
C. Sitagliptin
D. Empagliflozin
Answer: B
Rationale: Metformin is contraindicated when eGFR is below 30 mL/min due to increased risk of
lactic acidosis. Liraglutide (GLP-1 agonist) and sitagliptin (DPP-4 inhibitor) are generally safe
with dose adjustment. Empagliflozin (SGLT2 inhibitor) can be used down to eGFR 25 but
requires monitoring; however, it does not carry the same lactic acidosis risk as metformin.
3. A patient on long-term warfarin therapy is started on rifampin for tuberculosis. How
will their INR likely change, and what dose adjustment is needed?
A. INR increases; warfarin dose should be reduced
B. INR decreases; warfarin dose should be increased
C. INR increases; warfarin dose should be increased
D. INR decreases; warfarin dose should be reduced
Answer: B
Page 1
,Rationale: Rifampin is a potent CYP450 inducer, accelerating warfarin metabolism and leading to decreased INR and
reduced anticoagulant effect. Therefore, warfarin dose needs to be increased to maintain therapeutic INR. Option A describes
the opposite (inhibition), C and D are incorrect combinations.
4. A patient is receiving vancomycin for a serious MRSA infection. Trough levels are drawn
and reported as 8 mcg/mL. According to current consensus guidelines, what is the most
appropriate action?
A. Continue current dose; target trough is 5-10 mcg/mL
B. Increase dose; target trough is 15-20 mcg/mL for complicated infections
C. Decrease dose; trough is supratherapeutic
D. Hold dose and repeat level in 24 hours
Answer: B
Rationale: For serious MRSA infections (e.g., bacteremia, endocarditis, osteomyelitis), current
guidelines recommend vancomycin trough concentrations of 15-20 mcg/mL to optimize
pharmacokinetic/pharmacodynamic targets (AUC/MIC). A trough of 8 mcg/mL is subtherapeutic
for complicated infections; thus dose increase is warranted. Option A applies to uncomplicated
infections, C and D are incorrect.
5. Which of the following drug pairs shares the same mechanism of action at the cellular
level?
A. Metoprolol and carvedilol
B. Lisinopril and losartan
C. Furosemide and spironolactone
D. Amlodipine and nifedipine
Answer: D
Rationale: Amlodipine and nifedipine are both dihydropyridine calcium channel blockers that
inhibit L-type calcium channels in vascular smooth muscle. Metoprolol is a 1-selective blocker,
while carvedilol is a nonselective -blocker with 1-blocking activity (different mechanisms).
Lisinopril is an ACE inhibitor; losartan is an ARB. Furosemide is a loop diuretic;
spironolactone is a potassium-sparing diuretic (aldosterone antagonist).
6. A patient is receiving IV dobutamine for acute decompensated heart failure. Which
receptor activation primarily mediates its positive inotropic effect?
A. 1-adrenergic receptors
B. 2-adrenergic receptors
C. 1-adrenergic receptors
D. Dopamine D1 receptors
Answer: A
Rationale: Dobutamine is a synthetic catecholamine that primarily stimulates ²1-adrenergic
receptors in the heart, increasing contractility and cardiac output. 2 stimulation causes mild
vasodilation, 1 stimulation is minimal, and D1 receptor activation is not significant. The correct
Page 2
,answer is 1.
7. A patient on lithium therapy for bipolar disorder develops polyuria, polydipsia, and a
serum lithium level of 1.2 mEq/L (therapeutic range 0.6-1.2). Which adverse effect is most
likely?
A. Nephrogenic diabetes insipidus
B. Diabetes mellitus
C. Syndrome of inappropriate antidiuretic hormone secretion
D. Acute kidney injury
Answer: A
Rationale: Lithium can cause nephrogenic diabetes insipidus (NDI) by impairing the kidney's
response to antidiuretic hormone, leading to polyuria and polydipsia. This can occur even at
therapeutic levels. Diabetes mellitus is not a direct effect. SIADH would cause hyponatremia
and concentrated urine, opposite symptoms. Acute kidney injury is possible but less likely with
this level and presentation.
8. A patient receiving IV cyclophosphamide is at risk for hemorrhagic cystitis. Which
prophylactic measure is most effective in reducing this risk?
A. Administering mesna with aggressive hydration
B. Alkalinizing urine with sodium bicarbonate
C. Reducing cyclophosphamide dose by 50%
D. Concurrent use of corticosteroids
Answer: A
Rationale: Hemorrhagic cystitis is caused by acrolein, a toxic metabolite of cyclophosphamide.
Mesna binds to acrolein in the bladder, and aggressive hydration dilutes the urine, both
reducing bladder exposure. Alkalinization is not standard; dose reduction may compromise
efficacy; corticosteroids do not prevent this toxicity.
9. A patient with severe hypertension is started on sodium nitroprusside infusion. Which of
the following is a critical monitoring parameter due to the risk of cyanide toxicity?
A. Serum lactate levels
B. Serum potassium levels
C. Serum creatinine levels
D. Serum calcium levels
Answer: A
Rationale: Sodium nitroprusside is metabolized to cyanide, which can cause lactic acidosis by
inhibiting cellular respiration. Rising serum lactate is an early sign of cyanide toxicity.
Potassium, creatinine, and calcium are not directly related to this toxicity.
Page 3
, 10. A patient on digoxin therapy develops nausea, blurred vision, and ventricular bigeminy.
Serum digoxin level is 2.8 ng/mL (therapeutic 0.8-2.0). Which electrolyte abnormality most
predisposes to digoxin toxicity?
A. Hyperkalemia
B. Hypokalemia
C. Hypercalcemia
D. Hypomagnesemia
Answer: B
Rationale: Hypokalemia increases the binding of digoxin to the Na+/K+ ATPase, potentiating its
toxic effects even at lower serum levels. Hyperkalemia actually decreases binding.
Hypercalcemia can increase sensitivity but hypokalemia is the most common predisposing
factor. Hypomagnesemia also predisposes but is less directly implicated than hypokalemia.
11. A patient receiving a statin develops diffuse myalgia and elevated creatine kinase.
Which pharmacogenomic variant is most associated with increased risk of this adverse
effect?
A. CYP2D6 poor metabolizer status
B. SLCO1B1 c.521T>C polymorphism
C. CYP3A4*22 allele
D. ABCB1 C3435T variant
Answer: B
Rationale: The SLCO1B1 c.521T>C polymorphism reduces hepatic uptake of statins, increasing
systemic exposure and risk of myopathy. CYP2D6 is relevant for beta-blockers and
antidepressants. CYP3A4*22 affects metabolism of some statins but is less strongly associated
with myopathy. ABCB1 affects P-glycoprotein transport.
12. Which of the following best describes the mechanism of action of romosozumab in
osteoporosis treatment?
A. Inhibition of RANKL, reducing osteoclast activity
B. Selective estrogen receptor modulation in bone
C. Dual inhibition of sclerostin, increasing both bone formation and decreasing resorption
D. Parathyroid hormone receptor agonism, stimulating bone turnover
Answer: C
Rationale: Romosozumab is a monoclonal antibody against sclerostin, which enhances osteoblast
activity (bone formation) and reduces osteoclast activity (resorption). Denosumab inhibits
RANKL (A). Raloxifene is a SERM (B). Teriparatide is a PTH analog (D).
13. A patient on warfarin requires urgent reversal for life-threatening bleeding. Which
reversal agent is most appropriate if the patient has a mechanical heart valve?
A. Vitamin K 10 mg intravenous
Page 4
Verified Solutions
1. A patient receiving IV heparin develops a rapid drop in platelet count from 200,000 to
50,000/mm³ after 5 days of therapy. Which antibody is most likely responsible for this
complication?
A. IgA against heparin-platelet factor 4 complex
B. IgG against heparin-platelet factor 4 complex
C. IgM against heparin-antithrombin III complex
D. IgE against heparin-thrombomodulin complex
Answer: B
Rationale: Heparin-induced thrombocytopenia (HIT) is caused by IgG antibodies that bind to
heparin-platelet factor 4 complexes, activating platelets and leading to thrombocytopenia. IgA
and IgM are not the primary immunoglobulins involved. IgE is associated with allergic
reactions, not HIT.
2. A patient with type 2 diabetes mellitus and chronic kidney disease (eGFR 25 mL/min) is
being prescribed a new antihyperglycemic agent. Which of the following would be
contraindicated due to increased risk of lactic acidosis?
A. Liraglutide
B. Metformin
C. Sitagliptin
D. Empagliflozin
Answer: B
Rationale: Metformin is contraindicated when eGFR is below 30 mL/min due to increased risk of
lactic acidosis. Liraglutide (GLP-1 agonist) and sitagliptin (DPP-4 inhibitor) are generally safe
with dose adjustment. Empagliflozin (SGLT2 inhibitor) can be used down to eGFR 25 but
requires monitoring; however, it does not carry the same lactic acidosis risk as metformin.
3. A patient on long-term warfarin therapy is started on rifampin for tuberculosis. How
will their INR likely change, and what dose adjustment is needed?
A. INR increases; warfarin dose should be reduced
B. INR decreases; warfarin dose should be increased
C. INR increases; warfarin dose should be increased
D. INR decreases; warfarin dose should be reduced
Answer: B
Page 1
,Rationale: Rifampin is a potent CYP450 inducer, accelerating warfarin metabolism and leading to decreased INR and
reduced anticoagulant effect. Therefore, warfarin dose needs to be increased to maintain therapeutic INR. Option A describes
the opposite (inhibition), C and D are incorrect combinations.
4. A patient is receiving vancomycin for a serious MRSA infection. Trough levels are drawn
and reported as 8 mcg/mL. According to current consensus guidelines, what is the most
appropriate action?
A. Continue current dose; target trough is 5-10 mcg/mL
B. Increase dose; target trough is 15-20 mcg/mL for complicated infections
C. Decrease dose; trough is supratherapeutic
D. Hold dose and repeat level in 24 hours
Answer: B
Rationale: For serious MRSA infections (e.g., bacteremia, endocarditis, osteomyelitis), current
guidelines recommend vancomycin trough concentrations of 15-20 mcg/mL to optimize
pharmacokinetic/pharmacodynamic targets (AUC/MIC). A trough of 8 mcg/mL is subtherapeutic
for complicated infections; thus dose increase is warranted. Option A applies to uncomplicated
infections, C and D are incorrect.
5. Which of the following drug pairs shares the same mechanism of action at the cellular
level?
A. Metoprolol and carvedilol
B. Lisinopril and losartan
C. Furosemide and spironolactone
D. Amlodipine and nifedipine
Answer: D
Rationale: Amlodipine and nifedipine are both dihydropyridine calcium channel blockers that
inhibit L-type calcium channels in vascular smooth muscle. Metoprolol is a 1-selective blocker,
while carvedilol is a nonselective -blocker with 1-blocking activity (different mechanisms).
Lisinopril is an ACE inhibitor; losartan is an ARB. Furosemide is a loop diuretic;
spironolactone is a potassium-sparing diuretic (aldosterone antagonist).
6. A patient is receiving IV dobutamine for acute decompensated heart failure. Which
receptor activation primarily mediates its positive inotropic effect?
A. 1-adrenergic receptors
B. 2-adrenergic receptors
C. 1-adrenergic receptors
D. Dopamine D1 receptors
Answer: A
Rationale: Dobutamine is a synthetic catecholamine that primarily stimulates ²1-adrenergic
receptors in the heart, increasing contractility and cardiac output. 2 stimulation causes mild
vasodilation, 1 stimulation is minimal, and D1 receptor activation is not significant. The correct
Page 2
,answer is 1.
7. A patient on lithium therapy for bipolar disorder develops polyuria, polydipsia, and a
serum lithium level of 1.2 mEq/L (therapeutic range 0.6-1.2). Which adverse effect is most
likely?
A. Nephrogenic diabetes insipidus
B. Diabetes mellitus
C. Syndrome of inappropriate antidiuretic hormone secretion
D. Acute kidney injury
Answer: A
Rationale: Lithium can cause nephrogenic diabetes insipidus (NDI) by impairing the kidney's
response to antidiuretic hormone, leading to polyuria and polydipsia. This can occur even at
therapeutic levels. Diabetes mellitus is not a direct effect. SIADH would cause hyponatremia
and concentrated urine, opposite symptoms. Acute kidney injury is possible but less likely with
this level and presentation.
8. A patient receiving IV cyclophosphamide is at risk for hemorrhagic cystitis. Which
prophylactic measure is most effective in reducing this risk?
A. Administering mesna with aggressive hydration
B. Alkalinizing urine with sodium bicarbonate
C. Reducing cyclophosphamide dose by 50%
D. Concurrent use of corticosteroids
Answer: A
Rationale: Hemorrhagic cystitis is caused by acrolein, a toxic metabolite of cyclophosphamide.
Mesna binds to acrolein in the bladder, and aggressive hydration dilutes the urine, both
reducing bladder exposure. Alkalinization is not standard; dose reduction may compromise
efficacy; corticosteroids do not prevent this toxicity.
9. A patient with severe hypertension is started on sodium nitroprusside infusion. Which of
the following is a critical monitoring parameter due to the risk of cyanide toxicity?
A. Serum lactate levels
B. Serum potassium levels
C. Serum creatinine levels
D. Serum calcium levels
Answer: A
Rationale: Sodium nitroprusside is metabolized to cyanide, which can cause lactic acidosis by
inhibiting cellular respiration. Rising serum lactate is an early sign of cyanide toxicity.
Potassium, creatinine, and calcium are not directly related to this toxicity.
Page 3
, 10. A patient on digoxin therapy develops nausea, blurred vision, and ventricular bigeminy.
Serum digoxin level is 2.8 ng/mL (therapeutic 0.8-2.0). Which electrolyte abnormality most
predisposes to digoxin toxicity?
A. Hyperkalemia
B. Hypokalemia
C. Hypercalcemia
D. Hypomagnesemia
Answer: B
Rationale: Hypokalemia increases the binding of digoxin to the Na+/K+ ATPase, potentiating its
toxic effects even at lower serum levels. Hyperkalemia actually decreases binding.
Hypercalcemia can increase sensitivity but hypokalemia is the most common predisposing
factor. Hypomagnesemia also predisposes but is less directly implicated than hypokalemia.
11. A patient receiving a statin develops diffuse myalgia and elevated creatine kinase.
Which pharmacogenomic variant is most associated with increased risk of this adverse
effect?
A. CYP2D6 poor metabolizer status
B. SLCO1B1 c.521T>C polymorphism
C. CYP3A4*22 allele
D. ABCB1 C3435T variant
Answer: B
Rationale: The SLCO1B1 c.521T>C polymorphism reduces hepatic uptake of statins, increasing
systemic exposure and risk of myopathy. CYP2D6 is relevant for beta-blockers and
antidepressants. CYP3A4*22 affects metabolism of some statins but is less strongly associated
with myopathy. ABCB1 affects P-glycoprotein transport.
12. Which of the following best describes the mechanism of action of romosozumab in
osteoporosis treatment?
A. Inhibition of RANKL, reducing osteoclast activity
B. Selective estrogen receptor modulation in bone
C. Dual inhibition of sclerostin, increasing both bone formation and decreasing resorption
D. Parathyroid hormone receptor agonism, stimulating bone turnover
Answer: C
Rationale: Romosozumab is a monoclonal antibody against sclerostin, which enhances osteoblast
activity (bone formation) and reduces osteoclast activity (resorption). Denosumab inhibits
RANKL (A). Raloxifene is a SERM (B). Teriparatide is a PTH analog (D).
13. A patient on warfarin requires urgent reversal for life-threatening bleeding. Which
reversal agent is most appropriate if the patient has a mechanical heart valve?
A. Vitamin K 10 mg intravenous
Page 4
